Download PDF
Thromb Haemost 1982; 47(01): 032-035
DOI: 10.1055/s-0038-1657119
Original Article
Schattauer GmbH Stuttgart

Protection of Platelet Surface Bound Factors IX a and VIII Against Specific Inhibitors

Katalin Váradi
The Department of Blood Coagulation, National Institute of Haematology and Blood Transfusion, Budapest, Hungary
,
Susan Elödi
The Department of Blood Coagulation, National Institute of Haematology and Blood Transfusion, Budapest, Hungary
› Author Affiliations
Further Information

Publication History

Received 24 September 1981

Accepted 15 December 1981

Publication Date:
13 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The rate of inactivation of factors IX a and VIII as well as of the complex formed by them on the surface of platelets, induced by specific inhibitors has been studied. After the formation of complex both factors became more protected against high molecular weight inhibitors. As evidenced by the apparent first order inactivation rate constants, after complex formation the velocity of IX a – antithrombin III + heparin reaction fell to one-fourth, that of factor VIII – VIII : C antibody reaction decreased to 1/20. Enhanced resistance toward the high molecular weight inhibitors is presumably due to a steric change, since the low molecular weight phenylmethyl sulfonyl fluoride and diethyl pyrocarbonate inhibited free and complexed factor IX a to the same extent.

Key words

Factor IX a - Factor VIII - Platelets - Antithrombin III - Factor VIII: C antibody
 

  • References

  • 1 Hougie C, Denson KWE, Biggs RA. Study of the reaction product of factor VIII and IX by gel filtration. Thrombos Diathes Haemorrh 1967; 18: 211-222
    PubMedGoogle Scholar
  • 2 Hemker HC, Kahn MJP. Reaction sequence of blood coagulation. Nature 1967; 215: 1201-1202
    CrossrefPubMedGoogle Scholar
  • 3 Elödi S, Váradi K. Optimization of conditions for the catalytic effect of the factor IX a – factor VIII complex: Probable role of the complex in the amplification of blood coagulation. Thromb Res 1979; 15: 617-629
    CrossrefPubMedGoogle Scholar
  • 4 Váradi K, Elödi S. Increased resistance of factor IX a – factor VIII complex against inactivation by granulocyte proteases. Thromb Res 1980; 19: 571-578
    CrossrefPubMedGoogle Scholar
  • 5 Váradi K, Elödi S. Purification and properties of human factor IXa. Thromb Haemostas 1976; 35: 576-585
    PubMedGoogle Scholar
  • 6 Van Mourik JA, Mochtar IA. Purification of human antihaemophilic factor (factor VIII) by gel chromatography. Biochim Biophys Acta 1970; 221: 667-679
    PubMedGoogle Scholar
  • 7 Wickerhauser M, Williams C, Mercer J. Development of large scale fractionation methods. VII. Preparation of antithrombin concentrate. Vox Sang 1979; 36: 281-293
    CrossrefPubMedGoogle Scholar
  • 8 Kasper CK, Aledort LM, Counts RB. et al. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh 1975; 34: 871-872
    PubMedGoogle Scholar
  • 9 Joustra M, Lundgren H. Preparation of freeze-dried monomeric and immunochemically pure IgG by a rapid and reproducible chromatographic technique. In: Peeters H. Ed. Protides of Biological Fluids, Pergamon Press; Oxford: 1969
    Google Scholar
  • 10 Elödi S, Váradi K, Vörös E. Kinetics of formation of factor IX a – factor VIII complex on the surface of platelets. Thromb Res 1981; 21: 695-700
    CrossrefPubMedGoogle Scholar
  • 11 Ovádi J, Libor S, Elödi P. Spectrophotometric determination of histidine in proteins with diethyl pyrocarbonate. Acta Biochim Biophys Acad Sci Hung 1967; 2: 455-458
    PubMedGoogle Scholar
  • 12 Elödi S, Váradi K. Activation of clotting factors in prothrombin complex concentrates as demonstrated by clotting assays for factors IXa and Xa. Thromb Res 1978; 12: 797-807
    CrossrefPubMedGoogle Scholar
  • 13 Elödi S, Váradi K, Hollán SR. Some sources of error in the one-stage assay of factor VIII. Haemostasis 1978; 7: 1-9
    PubMedGoogle Scholar
  • 14 Ødegaard OR, Lie M, Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-294
    CrossrefPubMedGoogle Scholar
  • 15 Gjesdal K. Platelet factor 4 and antiheparin activity in plasma. In: Scully MF, Kakkar VV. Ed. Chromogenic Substrates: Chemistry and Clinical Usage, Churchill Livingstone Edinburgh; London: 1979
    Google Scholar
  • 16 Switzer MEP, Pizzo SV, McKee PA. Is there a precursive, relatively procoagulant inactive form of normal antihaemophilic factor (factor VIII)?. Blood 1979; 54: 916-929
    PubMedGoogle Scholar
  • 17 DiScipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61: 1528-1538
    CrossrefPubMedGoogle Scholar
  • 18 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin-phenol reagent. J Biol Chem 1951; 193: 265-275
    PubMedGoogle Scholar
  • 19 Davie EW, Fujikawa K, Kurachi K. The role of serine proteases in the blood coagulation cascade. Adv Enzymol 1979; 48: 277-319
    PubMedGoogle Scholar
  • 20 Miletich JP, Jackson CM, Majerus PW. Properties of factor Xa binding site on human platelets. J Biol Chem 1978; 253: 6908-6916
    PubMedGoogle Scholar
  • 21 James GT. Inactivation of the protease inhibitor phenyl-methylsulphonyl fluoride in buffers. Anal Biochem 1978; 86: 574-579
    CrossrefPubMedGoogle Scholar
  • 22 Melchior WB, Fahrney D. Ethoxyformation of proteins. Reaction of ethoxyformic anhydride with α-chymotrypsin and pancreatic ribonuclease at pH 4. Biochemistry 1970; 9: 251-258
    CrossrefPubMedGoogle Scholar
  • 23 Rosenberg JS, McKenna PW, Rosenberg RD. Inhibition of human factor IXa by human antithrombin III. J Biol Chem 1975; 250: 8883-8888
    PubMedGoogle Scholar
  • 24 Kurachi K, Fujikawa K, Schmer G, Davie EW. Inhibition of bovine factor IXa and factor Xa by antithrombin III. Biochemistry 1976; 15: 373-377
    CrossrefPubMedGoogle Scholar
  • 25 Barrowcliffe TW, Johnson EA, Thomas D. Antithrombin III and heparin. Br Med Bull 1978; 34: 143-150
    CrossrefPubMedGoogle Scholar